CO-1686 | CancerGRACE

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Article

Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

[powerpress]

Read more about CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Subscribe to CO-1686

Log in
FIGHT
EDUCATE
PARTICIPATE
- Community Forum
- Get Involved
  - Memorials and Tributes
  - Volunteer Opportunities
ABOUT CancerGRACE
DONATE
- Why Give to GRACE